The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
General Updates | Bispecific antibodies in Italy: current status and future outlooks
Claudio Cerchione, MD, PhD, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy, discusses recent advancements in Italy involving the reimbursement and registration of bispecific antibodies targeting CD3 and BCMA for treating multiple myeloma (MM). He highlights the effectiveness of these therapies, especially in achieving deep responses in a broader patient population outside of clinical trials, and underscores the importance of prophylaxis to mitigate infection risks. Dr Cerchione is optimistic about combining bispecific and monoclonal antibodies to create a potential new standard of care and hopes that future measurable residual disease (MRD)-guided treatment approaches will allow patients to enjoy a treatment-free remission. This interview took place virtually.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
